Dashboard
Manage Tickers

XFORX4 Pharmaceuticals, Inc

Nasdaq x4pharma.com


$ 1.05 $ -0.01 (-1.41 %)    

Friday, 10-May-2024 15:59:25 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 1.05
$ 1.10
$ 1.05 x 5,600
$ 1.06 x 5,800
$ 1.04 - $ 1.13
$ 0.57 - $ 2.58
3,982,510
na
209.99M
$ 1.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-21-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-19-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-04-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-11-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-09-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

x4-pharmaceuticals-announces-125m-capital-infusion-from-105m-sale-of-priority-review-voucher-and-20m-drawdown-from-existing-loan-facility-extends-projected-cash-runway-into-late-2025
X4 Pharmaceuticals Announces $125M Capital...
05/09/2024 11:23:59

x4-pharmaceuticals-q1-2024-gaap-eps-026-misses-016-estimate
X4 Pharmaceuticals Q1 2024 GAAP EPS $(0.26...
05/07/2024 10:04:32

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of ...

hc-wainwright--co-maintains-buy-on-x4-pharmaceuticals-raises-price-target-to-5
HC Wainwright & Co. Maintains Buy on X4 Ph...
04/30/2024 10:52:46

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the ...

fda-approves-x4-pharmaceuticals-mavorixafor-as-first-therapy-for-rare-immunodeficiency-disorder
FDA Approves X4 Pharmaceuticals' Mavorixaf...
04/29/2024 16:10:41

FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immu...

x4-pharmaceuticals-shares-are-trading-higher-after-the-fda-approved-the-companys-xolremdi-mavorixafor-for-whim-syndrome
X4 Pharmaceuticals shares are trading high...
04/29/2024 10:34:06

fda-approves-x4-pharmaceuticals-xolremdi-mavorixafor-capsules-for-use-in-patients-12-years-of-age-and-older-with-whim-syndrome-to-increase-the-number-of-circulating-mature-neutrophils-and-lymphocytes
FDA Approves X4 Pharmaceuticals' Xolremdi ...
04/29/2024 10:32:20

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
04/26/2024 16:31:22

hc-wainwright--co-reiterates-buy-on-x4-pharmaceuticals-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on X4 P...
03/22/2024 18:54:23

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains ...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
03/21/2024 17:31:11

earnings-scheduled-for-march-21-2024
Earnings Scheduled For March 21, 2024
03/21/2024 10:15:14

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...

recap-x4-pharmaceuticals-q4-earnings
Recap: X4 Pharmaceuticals Q4 Earnings
03/21/2024 10:15:06

x4-pharmaceuticals-q4-eps-010-beats-015-estimate
X4 Pharmaceuticals Q4 EPS $(0.10) Beats $(...
03/21/2024 10:02:49

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(...

x4-pharmaceuticalss-earnings-outlook
X4 Pharmaceuticals's Earnings Outlook
03/20/2024 16:01:50

b-riley-securities-downgrades-x4-pharmaceuticals-to-neutral-lowers-price-target-to-1
B. Riley Securities Downgrades X4 Pharmace...
12/12/2023 13:12:43

B. Riley Securities analyst Kalpit Patel downgrades X4 Pharmaceuticals (NASDAQ:XFOR) from Buy to Neutral and lowers the pric...

why-bluebird-bio-shares-are-trading-higher-here-are-other-stocks-moving-in-mondays-mid-day-session
Why bluebird bio Shares Are Trading Higher...
12/11/2023 18:12:59

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from ...

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
12/11/2023 17:30:56

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
12/11/2023 13:06:40

why-green-giant-shares-are-trading-lower-by-around-37-here-are-20-stocks-moving-premarket
Why Green Giant Shares Are Trading Lower B...
12/11/2023 12:59:28

Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Gre...

saturday-x4-pharmaceuticals-announced-presentation-of-additional-data-from-mavorixafor-phase-2-trial-in-chronic-neutropenia-at-ash-2023
Saturday, X4 Pharmaceuticals Announced Pre...
12/11/2023 11:58:11

Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic...

earnings-scheduled-for-november-9-2023
Earnings Scheduled For November 9, 2023
11/09/2023 11:52:51

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on re...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION